TSHA - Company ID 0001806310
The table below shows Taysha Gene Therapies, Inc.'s income statement line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | $9.77M | $8.33M | $15.45M | $2.50M | - | - |
| Cost of revenue | - | - | - | - | - | - |
| Gross profit | - | - | - | - | - | - |
| R&D | $86.40M | $66.00M | $56.78M | $91.17M | $131.94M | $31.89M |
| SG&A |
Taysha Gene Therapies, Inc. reported annual revenue of $9.77M for fiscal year 2025. That is up 17.3% from $8.33M in fiscal 2024. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| $33.87M |
| $28.95M |
| $30.05M |
| $37.36M |
| $41.32M |
| $11.11M |
| Operating income | -$110.50M | -$91.46M | -$72.44M | -$162.45M | -$173.27M | -$43.00M |
| Income tax | $0.00 | $0.00 | $0.00 | $0.00 | - | $0.00 |
| Net income | -$109.00M | -$89.30M | -$111.57M | -$166.01M | -$174.52M | -$60.01M |
| EPS (diluted) | -$0.34 | -$0.36 | -$0.96 | -$3.78 | -$4.64 | - |